Abstract
Semax is the first domestic nootropic drug of an unexhausted type from the group of neuropeptides. In experimental studies it showed angioprotective, antihypoxic and neurotrophic activity in the doses 100-150 micrograms/kg. A combined clinical-electrophysiologic study revealed its high efficiency in acute ischemic stroke. A clinical trial was performed of immunobiochemical mechanisms of neuroprotective properties of Semax in acute period of ischemic stroke. A retrospective comparative clinicoimmunobiochemical analysis provided objective data on the molecular level on activating influence of Semax on antiinflammatory postischemic reactions in the brain. Shifting neuromediatory balance toward a prevalence of the antiinflammatory agents (interleukin-10, tumor necrosis factor-alpha) over the factors maintaining the inflammation (interleukin-8, C-reactive protein).
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Acute Disease
-
Adrenocorticotropic Hormone / analogs & derivatives*
-
Adrenocorticotropic Hormone / therapeutic use
-
Brain / blood supply
-
Brain / drug effects*
-
Brain / immunology*
-
Brain Ischemia / cerebrospinal fluid
-
Brain Ischemia / drug therapy*
-
Brain Ischemia / immunology*
-
C-Reactive Protein / cerebrospinal fluid
-
C-Reactive Protein / immunology
-
Enzyme-Linked Immunosorbent Assay
-
Humans
-
Interleukin-10 / cerebrospinal fluid
-
Interleukin-10 / immunology
-
Neuroprotective Agents / pharmacology*
-
Neuroprotective Agents / therapeutic use*
-
Peptide Fragments / therapeutic use*
-
Retrospective Studies
-
Time Factors
-
Tumor Necrosis Factor-alpha / cerebrospinal fluid
-
Tumor Necrosis Factor-alpha / immunology
Substances
-
Neuroprotective Agents
-
Peptide Fragments
-
Tumor Necrosis Factor-alpha
-
Interleukin-10
-
ACTH (4-7), Pro-Gly-Pro-
-
Adrenocorticotropic Hormone
-
C-Reactive Protein